Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

Affiliations

¹ Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
² Kite Pharma, Santa Monica, CA, USA.
³ Medical Oncology/Hematology Fellowship Program, NCI, Bethesda, MD, USA.
⁴ Lymphoid Malignancy Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.
⁵ Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
⁶ Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
⁷ Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
⁸ Office of Regulatory Affairs, NCI, NIH, Bethesda, MD, USA.
⁹ Center for Cellular Engineering, Clinical Center, NIH, Bethesda, MD, USA.
¹⁰ Surgery Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.
¹¹ Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. kochendj@mail.nih.gov.

Published Erratum

Jennifer N Brudno et al. Nat Med. 2020 May.

. 2020 May;26(5):803.

doi: 10.1038/s41591-020-0864-x.

¹ Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.
² Kite Pharma, Santa Monica, CA, USA.
³ Medical Oncology/Hematology Fellowship Program, NCI, Bethesda, MD, USA.
⁴ Lymphoid Malignancy Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.
⁵ Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
⁶ Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
⁷ Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
⁸ Office of Regulatory Affairs, NCI, NIH, Bethesda, MD, USA.
⁹ Center for Cellular Engineering, Clinical Center, NIH, Bethesda, MD, USA.
¹⁰ Surgery Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.
¹¹ Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. kochendj@mail.nih.gov.

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.
Brudno JN, Lam N, Vanasse D, Shen YW, Rose JJ, Rossi J, Xue A, Bot A, Scholler N, Mikkilineni L, Roschewski M, Dean R, Cachau R, Youkharibache P, Patel R, Hansen B, Stroncek DF, Rosenberg SA, Gress RE, Kochenderfer JN. Brudno JN, et al. Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20. Nat Med. 2020. PMID: 31959992 Free PMC article. Clinical Trial.